Acharyya et al. described that the precise pharmacological inhibition of IKK resulted in decreased inflammation and, simultaneously, increased regeneration, implicating IKK/NF-κB as a suitable therapeutic target in DMD [39]. The gene discussed is NFKB1; the disease is Duchenne muscular dystrophy.